SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of car- diovascular outcome trials. Lancet. 2018. https://doi.org/10.1016/ S0140-6736(18)32590-X. 4.3. High Blood Cholesterol S4.3-1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082 1143. S4.3-2. Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.3-3. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181 92. S4.3-4. Cholesterol Treatment Trialists (CTT) Collaboration Herrington W, Emberson J, et al. Impact of renal function on the effects of LDL cho- lesterol lowering with statin-based regimens: a meta-analysis of indi- vidual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829 39. S4.3-5. Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force. Report No. 14-05206-EF-2. 2016. US Agency for Healthcare Research and Quality: Rockville, MD. Available at: http://www.ncbi.nlm.nih.gov/books/NBK396415. Accessed January 5, 2019. S4.3-6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cho- lesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615 22. S4.3-7. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. 